Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 25,005
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12551368 | Bioerodible ocular drug delivery insert and therapeutic method | 🖼🧊📄§ | 2026-02-17 | 2042-02-14 | 0 | 31 |
| 12552833 | Dynamics within supramolecuar IKVAV matrices enhance functional maturation of human IPSCS-derived neurons and regeneration | 🖼🧊📄§ | 2026-02-17 | 2040-01-24 | 0 | 31 |
| 12552773 | Compound for specifically enhancing spatial coupling degree of TRPV4-KCa2.3 complex and use thereof | 🖼🧊📄§ | 2026-02-17 | 2042-01-27 | 0 | 31 |
| 12552834 | Selective MENA binding peptides | 🖼🧊📄§ | 2026-02-17 | 2042-01-25 | 0 | 31 |
| 12551523 | HIF-1 activator | 🖼🧊📄§ | 2026-02-17 | 2042-10-04 | 0 | 31 |
| 12553041 | Formulations and doses of pegylated uricase | 🖼🧊📄§ | 2026-02-17 | 2040-06-04 | 0 | 31 |
| 12551547 | Highly networked immunogen composition | 🖼🧊📄§ | 2026-02-17 | 2040-03-12 | 0 | 31 |
| 12551471 | ABT-751 and ionizing radiation | 🖼🧊📄§ | 2026-02-17 | 2041-01-20 | 0 | 31 |
| 12551571 | Protease-cleavable substrates and methods of use thereof | 🖼🧊📄§ | 2026-02-17 | 2045-03-17 | 0 | 31 |
| 12552788 | IMDQ-PEG-CHOL adjuvant and uses thereof | 🖼🧊📄§ | 2026-02-17 | 2041-10-07 | 0 | 31 |
| 12552849 | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof | 🖼🧊📄§ | 2026-02-17 | 2044-09-09 | 0 | 31 |
| 12551558 | Compositions and methods for promoting hematopoietic cell cytotoxicity | 🖼🧊📄§ | 2026-02-17 | 2040-04-12 | 0 | 31 |
| 12552875 | Anti-human Cripto-1 antibody | 🖼🧊📄§ | 2026-02-17 | 2040-11-10 | 0 | 31 |
| 12551569 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | 🖼🧊📄§ | 2026-02-17 | 2045-03-30 | 0 | 31 |
| 12552852 | Chimeric antigen receptor t lymphocyte for treating tumors, preparation method therefor, and use thereof | 🖼🧊📄§ | 2026-02-17 | 2041-09-08 | 0 | 31 |
| 12553027 | Generation and cryopreservation of pluripotent stem cell-derived clinical grade corneal endothelial cells | 🖼🧊📄§ | 2026-02-17 | 2039-12-12 | 0 | 31 |
| 12551540 | Dosing and administration of recombinant L-asparaginase | 🖼🧊📄§ | 2026-02-17 | 2042-03-30 | 0 | 31 |
| 12552838 | Adeno-associated virus with engineered capsid | 🖼🧊📄§ | 2026-02-17 | 2041-04-19 | 0 | 31 |
| 12551515 | Methods and compositions for treating cancer | 🖼🧊📄§ | 2026-02-17 | 2039-11-21 | 0 | 31 |
| 12551541 | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | 🖼🧊📄§ | 2026-02-17 | 2044-06-25 | 0 | 31 |
| 12552810 | Crystalline forms of CFTR modulators | 🖼🧊📄§ | 2026-02-17 | 2041-08-12 | 0 | 31 |
| 12551505 | Composition for bone regeneration comprising METTL7A overexpressing stem cells, method for preparing same, and cell therapy product comprising same | 🖼🧊📄§ | 2026-02-17 | 2041-06-18 | 0 | 31 |
| 12551557 | Targeted chimeric antigen receptor modified T cells for treatment of IL13RALPHA2 positive malignancies | 🖼🧊📄§ | 2026-02-17 | 2041-03-12 | 0 | 31 |
| 12552797 | Process for making (3-[cyclopropylethoxy(difluoro)methyl]-6-6[5-fluoro-6-(2,2,2-trifluoroethoxy-3-pyridyl]- [1,2,4]triazolo[4,3-a]pyrazine | 🖼🧊📄§ | 2026-02-17 | 2040-11-25 | 0 | 31 |
| 12553048 | Multi-targeted siRNA for treating cancers | 🖼🧊📄§ | 2026-02-17 | 2040-12-11 | 0 | 31 |
| 12552871 | Nucleic acids encoding humanized anti-NGF antibodies | 🖼🧊📄§ | 2026-02-17 | 2041-03-12 | 0 | 31 |
| 12551468 | Pharmaceutical composition for oral administration, for treatment of liver cancer | 🖼🧊📄§ | 2026-02-17 | 2040-11-25 | 0 | 31 |
| 12552869 | CSF-1R antibodies for the treatment of chronic graft versus host disease | 🖼🧊📄§ | 2026-02-17 | 2040-12-09 | 0 | 31 |
| 12551546 | Materials and methods relating to immunogenic epitopes from human papilloma virus | 🖼🧊📄§ | 2026-02-17 | 2044-03-06 | 0 | 31 |
| 12551527 | Drug delivery systems for treatment of infections | 🖼🧊📄§ | 2026-02-17 | 2038-12-28 | 0 | 31 |
| 12551449 | Tunable degradation in hydrogel microparticles | 🖼🧊📄§ | 2026-02-17 | 2040-06-05 | 0 | 31 |
| 12551475 | Methods and compositions for treating RNA viral infections | 🖼🧊📄§ | 2026-02-17 | 2041-06-01 | 0 | 31 |
| 12551495 | Phytoecdysones and derivatives thereof for use in treating disordered respiratory function on viral infection | 🖼🧊📄§ | 2026-02-17 | 2041-03-24 | 0 | 31 |
| 12552848 | Hydrochloride salts of C5a receptor agonist peptides | 🖼🧊📄§ | 2026-02-17 | 2038-06-12 | 0 | 31 |
| 12552792 | Solid forms of an FGFR inhibitor and processes for preparing the same | 🖼🧊📄§ | 2026-02-17 | 2042-09-12 | 0 | 31 |
| 12552835 | Composition comprising Regentide-012 or Regentide-013 for improving skin condition | 🖼🧊📄§ | 2026-02-17 | 2041-06-08 | 0 | 31 |
| 12552754 | Leflutrozole compositions of matter and processes for preparation | 🖼🧊📄§ | 2026-02-17 | 2045-07-23 | 0 | 31 |
| 12551556 | Endogenous tumor-derived circular RNA and proteins thereof for use as vaccine | 🖼🧊📄§ | 2026-02-17 | 2038-12-27 | 0 | 31 |
| 12552840 | Identification of inhibitor peptides to bind with n-terminal spike (s) and nonstructural protein (NSP) sequences of SARS-COV2 b.1.617.2 Delta or Omicron variants alone and combination with drug(s) for targeted antiviral therapy | 🖼🧊📄§ | 2026-02-17 | 2042-05-04 | 0 | 31 |
| 12552846 | Modified BCL9 mimetic peptides | 🖼🧊📄§ | 2026-02-17 | 2040-07-06 | 0 | 31 |
| 12551498 | Treatment of P53-deficient cancers | 🖼🧊📄§ | 2026-02-17 | 2040-07-27 | 0 | 31 |
| 12544424 | Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins | 🖼🧊📄§ | 2026-02-10 | 2043-07-03 | 0 | 31 |
| 12544444 | Administration of tailored feedstock to increase antibiotic susceptibility | 🖼🧊📄§ | 2026-02-10 | 2039-08-22 | 0 | 31 |
| 12544386 | Method and composition for treatment of skin diseases associated with accelerated corneodesmosomes degradation or weaker cell-cell adhesion | 🖼🧊📄§ | 2026-02-10 | 2040-05-13 | 0 | 31 |
| 12544441 | Compositions comprising CelTOS immunogens and antibodies and method of use thereof | 🖼🧊📄§ | 2026-02-10 | 2043-03-23 | 0 | 31 |
| 12544414 | Lactobacillus reuteri and use, composition, drug and food thereof | 🖼🧊📄§ | 2026-02-10 | 2042-04-13 | 0 | 31 |
| 12544443 | Photodynamic therapy comprising two light exposures at different wavelengths | 🖼🧊📄§ | 2026-02-10 | 2043-03-22 | 0 | 31 |
| 12545673 | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient | 🖼🧊📄§ | 2026-02-10 | 2040-08-31 | 0 | 31 |
| 12545657 | Small-molecule modulators of the orphan nuclear receptor TLX | 🖼🧊📄§ | 2026-02-10 | 2041-12-22 | 0 | 31 |
| 12544345 | Compounds and combinations thereof for treating neurological and psychiatric conditions | 🖼🧊📄§ | 2026-02-10 | 2045-06-25 | 0 | 31 |